DBV Technologies reported a net loss of $147 million for 2025, up from $113.9 million in 2024, while operating income rose to $5.6 million from $4.2 million the prior year. The increase in operating income was largely driven by higher eligible French research tax credits, which offset the broader rise in research and development and general‑administrative expenses. Cash and cash equivalents stood at $194.2 million on December 31 2025, a dramatic increase from $32.5 million at the end of 2024. Financing activities generated $276.2 million in 2025, primarily from a 2025 PIPE and an ATM facility, while operating cash outflows totaled $121.2 million.
The company’s cash position is projected to fund operations through the second quarter of 2027. This runway is supported by an additional $94 million in gross proceeds received in January 2026 from warrant exercises, which, combined with the 2025 financing, provides a robust liquidity cushion for the upcoming BLA submissions and potential commercialization of the Viaskin® Peanut Patch.
R&D expenses increased by $27.3 million in 2025, driven by pre‑commercial inventory, external clinical expenses for the COMFORT Toddlers study, and employee‑related costs for quality and regulatory resources. General‑and‑administrative expenses rose by $4.6 million, largely due to market research and additional roles for launch preparation, reflecting the company’s strategic investment in its commercial launch readiness.
The Viaskin® Peanut Patch program continues to advance, with positive topline results from the VITESSE Phase 3 trial reported on December 16, 2025. BLA submissions for ages 4‑7 are anticipated in the first half of 2026, and for ages 1‑3 in the second half of 2026, positioning the company to potentially bring the product to market if regulatory milestones are met.
"We entered 2025 with a clear set of priorities – strengthening our financial position, advancing our clinical development program (including completing VITESSE and initiating COMFORT Toddlers), and preparing for the BLA submission and commercialization of the VIASKIN® Peanut Patch in the United States, if approved." – Daniel Tassé, CEO. "I am pleased with our progress to date in enhancing DBV's capabilities and building a company ready for launch. Our focus on bringing the VIASKIN® Peanut Patch to peanut‑allergic children ages 1‑7 years remains unwavering." – Daniel Tassé, CEO. "VITESSE is the largest immunotherapy clinical trial ever conducted in food allergy and we are thrilled that the resulting clinical evidence supporting the VIASKIN Peanut patch is robust. With these data in hand, I am looking forward to submitting the BLA to the FDA, as planned, in the first half of 2026." – Daniel Tassé, CEO. "Building on the statistically significant topline results from the VITESSE Phase 3 study, the additional data presented at this year's AAAAI Annual Meeting suggest a broad and consistent treatment effect of the VIASKIN® Peanut Patch, regardless of baseline eliciting dose strata or study population analysis. The increases in eliciting dose seen are clinically meaningful and may reflect a reduced risk of an allergic reaction." – David Fleischer, M.D., Professor of Pediatrics at Children's Hospital Colorado and Global Principal Investigator of the VITESSE study.
Investors responded positively to the results, reflecting confidence in the Viaskin® Peanut Patch pipeline and the company’s strengthened financial position. The expanded cash runway and upcoming BLA submissions reinforce the company’s trajectory toward potential commercialization, while the continued investment in clinical development underscores its commitment to advancing the product through regulatory approval.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.